AU2025205426A1 — Controlled-release CNP agonists with increased NEP stability

USPTO Abstract

#$%^&*AU2025205426A120250731.pdf##### Abstract The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment. This data, for application number 2022209221, is current as of 2024-02-01 21:00 AEST Abstract Jul The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding 26 released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment. INTERNATIONAL This data, for application number 2022209221, is current as of 2024-02-01 21:00 AEST 20 24 20 06 59 02 F eb 2 02 4 This data, for application number 2024200659, is current as of 2025-07-14 12:06 AEST Abstract 20042000591 026Fleb 2024 The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment. This data, for application number 2024209889, is current as of 2024-02-04 22:06 AEST 20 25 20 54 26 14 J ul 2 02 5 A b s t r a c t 0 2 4 F e b 2 0 2 4 T h e p r e s e n t i n v e n t i o n r e l a t e s t o c o n t r o l l e d - r e l e a s e C N P a g o n i s t s h a v i n g a n a t l e a s t 5 - f o l d l o n g e r d e g r a d a t i o n h a l f - l i f e i n a n i n v i t r o N E P d e g r a d a t i o n a s s a y t h a n t h e c o r r e s p o n d i n g r e l e a s e d C N P a g o n i s t , t o p h a r m a c e u t i c a l c o m p o s i t i o n s c o m p r i s i n g s a i d c o n t r o l l e d - r e l e a s e C N P a g o n i s t , t h e i r u s e a n d t o m e t h o d s o f t r e a t m e n t . T h i s d a t a , f o r a p p l i c a t i o n n u m b e r 2 0 2 4 2 0 9 8 8 9 , i s c u r r e n t a s o f 2 0 2 4 - 0 2 - 0 4 1 2 : 0 6 A E S T